Today, on World Hypertension Day, DigitalHealth.London Launchpad’s Megi Health announces the UK launch of MEGI, an accessible and personalized digital health assistant for blood pressure management. hypertension.
Hypertension (high blood pressure) is the leading controllable risk factor for heart and circulatory disease in the UK, contributing to around 50% of heart attacks and strokes nationwide. Around 28 per cent of adults, a total of 15 million people, live with high blood pressure in the UK. It is further estimated that six to eight million people are living with undiagnosed or poorly managed hypertension, highlighting the urgent need for increased awareness and proactive health measures.
Developed in collaboration with Infobip and drawing on the expertise of the Croatian Magdalena Clinic for Cardiovascular Diseases, Megi Health is pleased to announce the launch of MEGI, an innovative digital solution tailored to the management of hypertension in the market British. As an accessible and personalized digital health assistant designed to address the multifaceted nature of hypertension, MEGI views health and behavioral factors as crucial in the management of high blood pressure. Having already helped more than 6,000 patients with diagnosis and treatment, MEGI streamlines patient engagement by providing educational resources, medication reminders and lifestyle advice.
MEGI makes me feel safe and comfortable, just like at the doctor, and I always feel better after using it.
Stipan
51 year old MEGI user
Through the DigitalHealth.London Launchpad program, Megi Health has ensured MEGI is fully compliant to operate in the UK, meeting essential regulations and strict standards for digital health technologies. Megi Health has implemented extensive security measures within MEGI to protect users and ensure compliance with the highest ethical and security protocols.
Megi Health is currently seeking partnerships to trial MEGI in UK hospitals, with the aim of evaluating various outcomes such as increased patient engagement, reduced healthcare provider burden, improved clinical indicators (e.g. average reduction and stability of blood pressure) as well as increased medication compliance. As part of these initiatives, researchers from King’s College London will conduct in-depth analyzes of all study data collected, deepening the understanding of the effectiveness and impact of MEGI.
To learn more about Megi Health and MEGI, please visit https://www.megi.ai/or contact Nina Sesto And Inès Knezevic.
The DigitalHealth.London Launchpad program is funded by the UK Government through the UK Shared Prosperity Fund (UKSPF). It is delivered by the Health Innovation Network (HIN) South London in partnership with the Office of Life Sciences, CW+, Medicity, NHS England, the Mayor of London and the Leveling Up Fund.
For more information, please visit https://www.gov.uk/government/publications/uk-
Shared Prosperity Fund prospectus.
